Navigation Links
Pharmasset to Present at Two Upcoming Investor Conferences
Date:11/10/2008

he treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, has completed a 4-week clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Richard E. T. Smith, Ph.D.

VP, Investor Relations and Corporate Communications

richard.smith@pharmasset.com

Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
2. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
3. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
4. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
5. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
6. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
7. Pharmasset Joins Russell 3000 Index
8. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
9. Pharmasset Selected to Join the NASDAQ Biotechnology Index
10. Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th
11. Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... OHAUS Corporation, a leading manufacturer and ... to release a new line of Water Analysis Meters ... over a century, the OHAUS brand has been synonymous ... world. Now in North America, OHAUS is demonstrating ... include water quality measurement. The OHAUS Starter Series will ...
(Date:5/26/2015)... , May 26, 2015   PDI ... solutions, today announced that Oakwood Healthcare in ... as the winning entry in Delivering ... professionals who display excellence in building collaborative relationships ... teams in healthcare facilities.  Oakwood ...
(Date:5/26/2015)... , May 26, 2015  A simple blood ... Science Center to detect early Alzheimer,s disease is a ... Detailed standardized guidelines that are needed before ... been published in Alzheimer,s & Dementia . The ... an international working group that includes UNT Health Science ...
(Date:5/26/2015)... ANGELES , May 26, 2015 Pharmaco-Kinesis ... Board (NOCAB) recently convened at Shutters on the Beach ... review the development status of the Company,s innovative Metronomic ... designed to locally deliver chemotherapy over time to a ... dose delivery capacity and biofeedback system in real-time.  ...
Breaking Biology Technology:OHAUS Corporation to Release New Water Analysis Meters in 2015 2OHAUS Corporation to Release New Water Analysis Meters in 2015 3PDI Announces Winner in Delivering the Difference Contest 2PDI Announces Winner in Delivering the Difference Contest 3Guidelines bring UNT Health Science Center's blood test for Alzheimer's one step closer 2Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 2Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 4Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 5
... Service Helps Hospitals and Health Systems Reduce the ... Medicaid Recovery Audit ContractorPHOENIX, Jan. 14 Arizona-based ... announced the launch of its new Government ... created as a pre-review process to assist hospitals ...
... 14 Accuray Incorporated,(Nasdaq: ARAY ), a global ... report results for its second quarter fiscal year 2009, ending,December ... closes. , A conference call to ... 5:00,p.m. EST and will be hosted by Euan S. Thomson, ...
... At the Boston Atrial,Fibrillation Symposium, Stereotaxis, Inc. ... in remote magnetic ablation that it believes will ... Magnetic Navigation,System. In booth #917, Stereotaxis will ... QuikCAS(TM) Cardiodrive(R) System for enhanced remote,catheter control and ...
Cached Biology Technology:Cain and Associates Launches Government Audit Protection (GAP) Service 2Cain and Associates Launches Government Audit Protection (GAP) Service 3Accuray Incorporated to Report Second Quarter Fiscal Year 2009 Financial Results 2Stereotaxis Showcases Advancements for Remote Magnetic Ablations 2Stereotaxis Showcases Advancements for Remote Magnetic Ablations 3Stereotaxis Showcases Advancements for Remote Magnetic Ablations 4
(Date:5/26/2015)... May 26, 2015 Research ... addition of the "Saudi Arabia Biometric Systems ... their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The biometric ... is projected to grow at over 22% ... is attributed to the surging demand for better ...
(Date:5/25/2015)... 25, 2015  Australia,s market for wearable technologies is ... saw the advent of several trials and prototypes. The ... is expected to ignite interest in wearables as well ... Australia . This in turn will spur greater ... new partnerships amongst vendors and distributors. ...
(Date:5/22/2015)... 22, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... be ending its promotional pricing and making the Wocket generally ... Laurence Savin , Head of Marketing said, "We,ve extended the ... the end of May. To get your wocket at this ... open the store on June 1, you,ll receive a unique ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3
... particularly neuroproteins that maintain proper brain function. ... known as "tangle diseases" because they are characterized by ... A team of Australian and American scientists discovered ... inserted into neuroproteins, causing them to misfold and aggregate. ...
... grants totaling more than $25 million over four years ... on the millions of genomic variants relevant to human ... useful for clinical practice. The awards are from the ... research centers are sequencing the DNA of whole genomes ...
... health care innovations, if brought to scale immediately in low-resource ... some 1.2 million mothers and children in 2015. ... children under 5 is 6.9 million. Between 2016-2020, ... nearly 7.5 million women and children. The ten, identified ...
Cached Biology News:Jackson Hole, Wyoming: New mechanism for protein misfolding may link to ALS 2New NIH-funded resource focuses on use of genomic variants in medical care 2New NIH-funded resource focuses on use of genomic variants in medical care 3Innovations save lives of mothers and children 2Innovations save lives of mothers and children 3Innovations save lives of mothers and children 4Innovations save lives of mothers and children 5Innovations save lives of mothers and children 6Innovations save lives of mothers and children 7
...
... / Mount is the standard water based ... especially for the permanent preservation of peroxidase ... is easy to use and exhibits excellent ... first aqueous mounting medium that permits the ...
... ZMD.368. Immunogen: Synthetic peptide derived ... human WNT2B/WNT13 protein. Specificity: Specific ... and rat WNT2B/WNT13 proteins. Recognizes both ... Reactivity: Mouse Human Rat (positive controls: ...
Immunogen: Heat inactivated bacterial cells of Salmonella enteriditis,paratyphi and typhimurium Storage: 4 C...
Biology Products: